CHEMECA DRUGS PRIVATE LTD

Overview

CHEMECA DRUGS PRIVATE LTD is an active pharmaceutical ingredient (API) supplier with 12 active FDA Type II Drug Master Files, covering BUPROPION HYDROCHLORIDE USP; CARISOPRODOL USP; CELECOXIB USP; CLOPIDOGREL BISULFATE USP; DILTIAZEM HYDROCHLORIDE USP; FEXOFENADINE HYDROCHLORIDE USP.

API / Drug Master Files

CHEMECA DRUGS PRIVATE LTD holds 12 active (12 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• FLUOXETINE HYDROCHLORIDE USPActive2025-09-30
• RIFAXIMINActive2025-09-19
• PIRFENIDONE USPActive2024-09-30
• HYDRALAZINE HCL USPActive2023-09-13
• CELECOXIB USPActive2023-01-12
• QUETIAPINE FUMARATE USPActive2022-07-26
• FEXOFENADINE HYDROCHLORIDE USPActive2021-12-15
• CLOPIDOGREL BISULFATE USPActive2021-02-05
• BUPROPION HYDROCHLORIDE USPActive2020-12-24
• CARISOPRODOL USPActive2020-09-28
• DILTIAZEM HYDROCHLORIDE USPActive2020-02-15
• SERTRALINE HYDROCHLORIDE USPActive2019-03-01

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to CHEMECA DRUGS PRIVATE LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.